Effecty and security of Gemcitabine and S-1 in the treatment of metastatic triple-negative breast cancer / 中华内分泌外科杂志

Objective To observe the effect and toxicity of gemcitabine and S-1 in treatment of metastatic triple-negative breast cancer.Methods In this study,41 cases of metastatic breast cancer were treated in the General Hospital of Shenyang Military Region between Jun.2010 and Dec.2012.The median age was 55 years old.The pathological diagnosis of these patients was triple-negative breast cancer.All patients were given gemcitabine 1000 mg/m2 intravenously on the 1st and 8th day,and 60 mg S-1 from the 1st day to the 14th day orally for every cycle.There were 21 days for each cycle.All patients accepted at least 2 cycles of chemotherapy and once effect evaluation.Results 41 cases were diagnosed as metastatic triple-negative breast cancer,with the failure of second-line treatment.The median age was 55 years.All cases were followed up until death.All the 41 cases were administrated for more than 2 cycles,among whom,there were 0 case of complete response(CR),16 cases (39.0％)of partial response(PR),14 cases(34.1％) of stable disease(SD),and 11 cases(26.8％) of progressive disease(PD).The disease control rate was 73.1％ (30/41).In this study,median progression free survival(mPFS)was 7.9 months.The rate of digestive toxicity and marrow suppression was 24.4％ and 55％ respectively.No patient stopped treatment because of severe toxicities.Conclusion The chemotherapy regimen of gemcitabine and S-1 is effective in treatment of metastatic triple-negative breast cancer,and the toxicity could be tolerated.

Clinical effect of Gefitinib(Iressa)in 51 cases of none-small cell lung cancer(NSCLC) / 中国实用内科杂志

Objective To ascertain clinical experience and toxic reactions of treating NSCLC by Gefitinib(Iressa).Methods Clinical data of 51 NSCLC cases were collected and analyzed who were treated with Iressa from Mar.2004 to Mar.2006.Evaluations were made about curative effects,quality of life,mean survival time,time to progression and toxic reactions.Results Fifty-one patients were all followed up.Total mitigative rate of the focus was 29.4%,total control rate was 66.7%,and alleviative rate of clinical symptoms was 62.7%.The difference of KPS grades in 4 weeks was significant.Mean survival time of all the patients was 8.2 months.Time to progression was 6.1 months.Ⅲ~Ⅳ grades of toxic reaction were not found.Conclusion Gefitinib may obviously improve the clinical symptom and QOL of the NSCLC patients,and it has good tolerance to treat NSCLC.It is a kind of molecule-target medicine suited with Chinese.